Selenium and the thyroid gland: more good news for clinicians

Authors

  • Anne Drutel,

    1. Department of Endocrinology and Metabolic diseases, Hôpital du Cluzeau, Limoges Cedex, France
    Search for more papers by this author
  • Françoise Archambeaud,

    1. Department of Endocrinology and Metabolic diseases, Hôpital du Cluzeau, Limoges Cedex, France
    Search for more papers by this author
  • Philippe Caron

    Corresponding author
    1. Department of Endocrinology and Metabolic diseases, Pôle cardio-vasculaire et métabolique, Toulouse Cedex 9, France
    • Department of Endocrinology and Metabolic diseases, Hôpital du Cluzeau, Limoges Cedex, France
    Search for more papers by this author

Correspondence: Philippe Caron, MD, Department of Endocrinology and Metabolic Diseases, CHU Rangueil-Larrey, 24 Chemin de Pourvouville, TSA 30030, 31059 Toulouse Cedex 9, France. Tel.: +33 5 67 77 17 01; Fax: +33 5 67 77 16 72; E-mail: caron.p@chu-toulouse.fr

Summary

The thyroid is the organ with the highest selenium content per gram of tissue because it expresses specific selenoproteins. Since the discovery of myxoedematous cretinism and thyroid destruction following selenium repletion in iodine- and selenium-deficient children, data on links between thyroid metabolism and selenium have multiplied. Although very minor amounts of selenium appear sufficient for adequate activity of deiodinases, thus limiting the impact of its potential deficiency on synthesis of thyroid hormones, selenium status appears to have an impact on the development of thyroid pathologies. The value of selenium supplementation in autoimmune thyroid disorders has been emphasized. Most authors attribute the effect of supplementation on the immune system to the regulation of the production of reactive oxygen species and their metabolites. In patients with Hashimoto's disease and in pregnant women with anti-TPO antibodies, selenium supplementation decreases anti-thyroid antibody levels and improves the ultrasound structure of the thyroid gland. Although clinical applications still need to be defined for Hashimoto's disease, they are very interesting for pregnant women given that supplementation significantly decreases the percentage of postpartum thyroiditis and definitive hypothyroidism. In Graves' disease, selenium supplementation results in euthyroidism being achieved more rapidly and appears to have a beneficial effect on mild inflammatory orbitopathy. A risk of diabetes has been reported following long-term selenium supplementation, but few data are available on the side effects associated with such supplementation and further studies are required.

Ancillary